Notice of Results | 12-Sep-2023 | 07:00 | RNS |
Holding(s) in Company | 31-Jul-2023 | 08:05 | RNS |
Director/PDMR Shareholding | 28-Jul-2023 | 08:28 | RNS |
Trading update | 25-Jul-2023 | 07:00 | RNS |
Shareholder Open Day and Notice of Trading Update | 12-Jul-2023 | 07:00 | RNS |
Exercise of Share Options and Total Voting Rights | 10-Jul-2023 | 07:00 | RNS |
Director/PDMR Shareholding | 26-Jun-2023 | 07:00 | RNS |
Holding(s) in Company | 22-Jun-2023 | 16:01 | RNS |
Exercise of Share Options and Total Voting Rights | 16-Jun-2023 | 07:00 | RNS |
Holding(s) in Company | 14-Jun-2023 | 16:10 | RNS |
Exercise of Share Options and Total Voting Rights | 06-Jun-2023 | 17:00 | RNS |
Analyst and Investor presentation | 05-Jun-2023 | 10:00 | RNS |
FDA De Novo approval | 05-Jun-2023 | 07:00 | RNS |
Issue of Equity | 28-Mar-2023 | 11:30 | RNS |
Successful submission of additional data to US FDA | 27-Mar-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 425.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 435.00 |
52 Week Low | 295.00 |
Volume | 8,688 |
Shares Issued | 47.31m |
Market Cap | £201.07m |
RiskGrade | 180 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 16-Mar-23 | 17-Nov-22 |
Paid | 11-Apr-23 | 16-Dec-22 |
Amount | 2.62p | 3.93p |
Time | Volume / Share Price |
09:29 | 376 @ 423.45p |
09:24 | 710 @ 423.45p |
09:13 | 377 @ 423.45p |
09:06 | 4,725 @ 423.45p |
08:15 | 2,500 @ 423.42p |
CEO | Paul Christopher Swinney |
Finance Director | Elizabeth Dixon |
You are here: research